This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the Phase 3 LELANTOS data of FibroGen's Pamrevlumab in patients with non-ambulatory DMD

Ticker(s): FGEN

Who's the expert?

Institution: Children's Hospital of Richmond (at VCU)

  • Assistant Professor, Division of Child Neurology at VCU & Dual-board certified child neurologist and neuromuscular physician.
  • Currently treats 60 to 70 patients with DMD.
  • Clinical and research interests are in pediatric neuromuscular disorders with a  particular focus on Duchenne Muscular Dystrophy; has served as the PI of several clinical trials in DMD and site investigator for Exon 51.

Interview Questions

What are your high level thoughts, including  familiarity with this program even before we approached you with this topic?

Added By: slingshot_insights

What are personal thoughts on targeting CTGF as just a general idea in DMD? Are you more optimistic or pessimistic about this pathway making a big difference in these patients?

Added By: slingshot_insights

Could you talk about the natural history of DMD? For the 46 patients in the placebo arm what your expectation would be after 104 weeks, what kind of FVC decline would you expect, and is there even a possibility that the placebo arm would be stable?

Added By: slingshot_insights

Looking at upper limb performance, do you think that those all correlate together, or what's the chance that we might get a split result where there's really encouraging signs on one endpoint, but then on the others maybe not so much? 

Added By: slingshot_insights

If this drug did nothing else but stabilize the functional assessment, even if we don't know the effect size, would that be pretty likely to yield a positive outcome?

Added By: slingshot_insights

What is your level of confidence regarding the ambulatory trial, and is the North Star Ambulatory Assessment endpoint more difficult to hit as compared to the non-ambulatory trial endpoint?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.